Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . FDA label
Also known as Revefenacin Inhalation Solution [Yupelri]
Revefenacin · 1 trial · 2 indications
Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Static Resistance (Rstat) at the time of drug trough
| Arm | Type | Description |
|---|---|---|
| Revefenacin | EXPERIMENTAL | Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered. |
| Ipratropium | ACTIVE_COMPARATOR | Nebulized ipratropium will be delivered via nebulizer Q6 hours. |
| Name | Type | Description |
|---|---|---|
| Revefenacin Inhalation Solution [Yupelri] | DRUG | nebulized drug comparison |
| Ipratropium Bromide | DRUG | nebulized drug comparison |
Inclusion Criteria: * Adults ≥ 40 years of age * Acute respiratory failure requiring invasive mechanical ventilation * Documented history of COPD based on spirometric evidence of FEV1/FVC\<70% * Smoking history \>10 years (current or prior) * Invasive mechanical ventilation for \< 96 hours Exclusi...
Top 12 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 9 | PHASE3 | Depemokimab, GSK5784283, GSK3862995B |
| AstraZeneca PLC | AZN | 15 | PHASE3 | Tezepelumab, Breztri, Bevespi, Tozorakimab, AZD6793 |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Lunsekimig, SAR447537, Dupilumab |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Ensifentrine, Frespaciguat, LABA/LAMA |
| Pfizer Inc. | PFE | 2 | PHASE3 | tilrekimig and rHuPH20, PF-07275315 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Alpha-1 MP |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Astegolimab, RO7830698 |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | Tyvaso (treprostinil) |
| Bambusa Therapeutics | BBTX | 2 | PHASE1 | BBT002 |
Revefenacin is an investigational small molecule developed by Theravance Biopharma, Inc. (TBPH) for COPD. It is also known as Revefenacin Inhalation Solution [Yupelri]. It is being studied in a Phase 2 clinical program for respiratory disease, including a completed trial in COPD with acute respiratory insufficiency.
Revefenacin is being studied for COPD, including COPD with acute respiratory insufficiency. The Phase 2 trial NCT04315558 evaluated revefenacin in adults aged 40 years and older with COPD and acute respiratory failure. It is an investigational agent and is not established as a treatment outside of clinical research.
Revefenacin targets CHRM3, the M3 muscarinic acetylcholine receptor, and acts as an antagonist at this receptor. By blocking CHRM3, revefenacin is designed to interfere with cholinergic signaling in the airways, a mechanism relevant to respiratory conditions such as COPD.
Revefenacin is developed by Theravance Biopharma, Inc., which trades under the ticker TBPH. The company is the sponsor of the clinical program studying revefenacin in COPD and related respiratory conditions.
Revefenacin is in Phase 2 development for COPD. It is an investigational drug and is not approved by the FDA for this use. The Phase 2 program includes one completed trial, and no active trials are currently listed for revefenacin.
Revefenacin has been studied in the Phase 2 trial NCT04315558, titled Revefenacin in Acute Respiratory Insufficiency in COPD. The trial was completed, enrolled 21 participants, was randomized, double blind, and active controlled, and was conducted in the United States in adults aged 40 years and older.
Yes, revefenacin is also known as Revefenacin Inhalation Solution [Yupelri]. Both names refer to the same small molecule developed by Theravance Biopharma, Inc. (TBPH) and studied in COPD. Readers searching either name will find the same drug asset.